BPC-157 Capsules (60 × 500mcg)

Synthetic pentadecapeptide derived from a gastric protein sequence. A stable sequence of 15 amino acids lifted from a protective protein in human gastric juice, BPC-157 ranks among the most heavily cited repair peptides in the preclinical record. Several hundred rodent experiments have examined it across tendon, ligament, muscle, gut and nervous-system injury. Part of what sets it apart is its durability: it withstands stomach acid and stays active in solution for days.

Tendon and ligament: achilles and MCL transection models with biomechanical endpoints. Skeletal muscle: recovery from crush and denervation injury. Gastrointestinal protection: mucosal injury from NSAIDs and alcohol, plus inflammatory bowel models. Angiogenesis: vessel formation and VEGFR2 signalling at the injury site. Nervous system: models of peripheral nerve and spinal-cord injury. Accelerated healing against controls has been reported in rat Achilles tendon transection (Staresinic et al., J Orthop Res 2003), medial collateral ligament injury, muscle crush and gastric-ulcer models. Gut work shows the intestinal lining protected in NSAID-induced injury. The human record is thin, limited to small trials and case series, and no controlled human trial exists.

In rat tendon-transection work, treated tendons gained biomechanical strength and better-organised collagen inside a few weeks; ligament and muscle-crush models reported quicker functional recovery; gut models reported smaller lesion scores. Human 'before and after' photos form no part of the published record.

No consistent toxicity shows up in the rodent literature, though a controlled human safety study is missing. Reviews flag theoretical issues such as angiogenic activity where tumours are present and the lack of long-term data. WADA prohibits it.

In the published BPC-157 research, the amounts used were 10 mg total, injection around the inflamed bladder area, Once, during a single procedure in human pilot, interstitial cystitis (Lee E et al. (2024)); 10 mg IV (day 1), 20 mg IV (day 2), each in 250 cc saline over 1 h, Once daily on 2 days in human safety pilot (Lee E et al. (2025)); 200 or 2 μg/kg intraperitoneal, Once, 10 min after injury in rat, spinal cord injury (Perovic D et al. (2019)). These are the figures each study reports for its own model, listed in full in the dosage table on this page with links to PubMed. Peptide Aus supplies BPC-157 for in-vitro research and does not give dosing guidance for people.

We keep both. The vial matches the format used in the tendon, muscle and nerve studies; the 500 mcg capsules fit oral and gut designs, where the earliest BPC-157 research belongs.

A different route of action: BPC-157 signals through nitric oxide and growth factors, whereas TB-500 works via the actin cytoskeleton and cell migration, which is why researchers frequently pair them.

The 'Wolverine stack' is forum slang for BPC-157 paired with TB-500; Peptide Aus carries that combination as a pre-blended vial.

We stock both. Reconstituted from the 10mg lyophilised vial, the solution fits the systemic, tendon and muscle designs that most of the literature used. The capsules hold 500 mcg of BPC-157 apiece, 60 to a bottle, and are suited to oral and gastrointestinal work where the peptide targets the gut lining. Either format comes with a batch certificate on request.

BPC-157 is the shortest fragment of a parent protein, isolated from human gastric juice, that retains the protein's stomach-lining protection. That is the reason the first studies looked at ulcer models.

It does. In 2022 the World Anti-Doping Agency listed BPC-157 as a non-approved substance on its Prohibited List, which matters for any research that involves athletes.

In gut-injury models, oral BPC-157 produced protective effects. For musculoskeletal and systemic research questions the published work used the peptide in solution; see our capsules-versus-vial guide.

Sealed, below 25 °C, away from moisture and light.

No registered BPC-157 medicine exists anywhere, and the TGA has not approved the peptide for any human use. Within Australia, supplying it for human use sits under the prescription-only schedule of the Poisons Standard, and the TGA has acted against companies that market it that way. Peptide Aus provides BPC-157 strictly as a research reagent for in-vitro laboratory work, and responsibility for lawful use rests with the buyer. Our guide covers the legal status of BPC-157 in Australia.

Directly from Peptide Aus, from Australian stock. Paid orders before 2pm AEST/AEDT dispatch the same business day, tracked.